Through its K171 domain, ALYREF recognizes RABL6 and TK1 mRNA m5C modification, promoting their mRNA splicing and stability to increase bladder cancer malignancy (Wang et al., 2023b). Here, RABL6 is linked to urinary bladder carcinoma.